Rosiglitazone in the UK: down but not out

Iheanacho talks about the statement released by MHRA (Medicines and Healthcare Products Regulatory Agency) about the drug rosiglitazone. It's essentially a brief summary of the view of the agency, and that of the European Medicines Agency (EMEA), on the safety of this diabetes medicine. Its pre...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 2010-04, Vol.340 (apr07 2), p.c1849-c1849
Main Author: Iheanacho, Ike
Format: Article
Language:English
Subjects:
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Drug Approval
Drugs
Humans
Hypoglycemic Agents - adverse effects
Product safety
Regulatory agencies
Side effects
Thiazolidinediones - adverse effects
United Kingdom
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iheanacho talks about the statement released by MHRA (Medicines and Healthcare Products Regulatory Agency) about the drug rosiglitazone. It's essentially a brief summary of the view of the agency, and that of the European Medicines Agency (EMEA), on the safety of this diabetes medicine. Its presence and content, though, are a bit odd. The message is that EMEA completed a thorough review of the safety of the thiazolidinediones--the class from which the drug comes--in 2007, concluding that "the balance of risks and benefits of rosiglitazone remain favorable in its licensed indications."
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.c1849